4.6 Article

Changing Trends in the Global Consumption of Treatments Used in Hospitalized Patients for COVID-19: A Time Series Multicentre Study

Journal

ANTIBIOTICS-BASEL
Volume 12, Issue 5, Pages -

Publisher

MDPI
DOI: 10.3390/antibiotics12050809

Keywords

SARS-CoV-2; treatment trends; antiviral drugs; immunomodulatory drugs; antibiotics; COVID-19 treatments

Ask authors/readers for more resources

This study analyzed the prescription trends of COVID-19 treatments for hospitalized patients in Barcelona. The use of lopinavir/ritonavir and hydroxychloroquine declined over time and was replaced by remdesivir. Tocilizumab use showed a varying trend, while dexamethasone use increased. Antibiotic use, particularly azithromycin, decreased after the initial months of the pandemic. The findings highlight the importance of adapting treatment strategies based on evolving scientific evidence.
Aim: To analyze trends in the prescription of COVID-19 treatments for hospitalized patients during the pandemic. Methods: Multicenter, ecological, time-series study of aggregate data for all adult patients with COVID-19 treated in five acute-care hospitals in Barcelona, Spain, between March 2020 and May 2021. Trends in the monthly prevalence of drugs used against COVID-19 were analyzed by the Mantel-Haenszel test. Results: The participating hospitals admitted 22,277 patients with COVID-19 during the study period, reporting an overall mortality of 10.8%. In the first months of the pandemic, lopinavir/ritonavir and hydroxychloroquine were the most frequently used antivirals, but these fell into disuse and were replaced by remdesivir in July 2020. By contrast, the trend in tocilizumab use varied, first peaking in April and May 2020, declining until January 2021, and showing a discrete upward trend thereafter. Regarding corticosteroid use, we observed a notable upward trend in the use of dexamethasone 6 mg per day from July 2020. Finally, there was a high prevalence of antibiotics use, especially azithromycin, in the first three months, but this decreased thereafter. Conclusions: Treatment for patients hospitalized with COVID-19 evolved with the changing scientific evidence during the pandemic. Initially, multiple drugs were empirically used that subsequently could not demonstrate clinical benefit. In future pandemics, stakeholders should strive to promote the early implementation of adaptive randomized clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available